These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 29198)

  • 61. Early supersensitive changes in [3H] spiroperidol binding in the isolated striatum.
    Csernansky JG; Friedhoff AJ; Bonnet KA
    Biochem Biophys Res Commun; 1982 Mar; 105(1):117-20. PubMed ID: 6124243
    [No Abstract]   [Full Text] [Related]  

  • 62. Quantitative analysis of [3H]spiroperidol binding to rat forebrain sections: plasticity of neostriatal dopamine receptors after nigrostriatal injury.
    Neve KA; Altar CA; Wong CA; Marshall JF
    Brain Res; 1984 Jun; 302(1):9-18. PubMed ID: 6428705
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Reduction of 3H-spiroperidol binding in rat striatum and frontal cortex by chronic amphetamine: dose response, time course and role of sustained dopamine release.
    Nielsen EB; Nielsen M; Braestrup C
    Psychopharmacology (Berl); 1983; 81(1):81-5. PubMed ID: 6415736
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Are striatal [3H]spiperone radioreceptor assays indicative of multiple dopamine receptor interactions?
    Clements-Jewery S; Robson PA
    Neuropharmacology; 1981 Dec; 20(12B):1295-8. PubMed ID: 7322304
    [No Abstract]   [Full Text] [Related]  

  • 65. Turnover of specific [3H]spiperone and [3H]N,n-propylnorapomorphine binding sites in rat striatum following phenoxybenzamine administration.
    Hall MD; Jenner P; Marsden CD
    Biochem Pharmacol; 1983 Oct; 32(19):2973-7. PubMed ID: 6626267
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Agonist interactions with [3H]-spiperone binding sites on rat corpus striatum membranes [proceedings].
    Howlett DR; Morris H; Nahorski SR
    Br J Pharmacol; 1979 May; 66(1):136P. PubMed ID: 454928
    [No Abstract]   [Full Text] [Related]  

  • 67. Distinction between dopaminergic and serotonergic components of neuroleptic binding sites in limbic brain areas.
    Leysen JE; Gommeren W; Laduron PM
    Biochem Pharmacol; 1979; 28(3):447-8. PubMed ID: 34403
    [No Abstract]   [Full Text] [Related]  

  • 68. 2-Amino-6-chloro-4-(N-methylpiperazino)pyrimidines, inhibitors of spiroperidol binding.
    Guérémy C; Audiau F; Uzan A; Le Fur G; Léger JM; Carpy A
    J Med Chem; 1982 Dec; 25(12):1459-65. PubMed ID: 7154006
    [TBL] [Abstract][Full Text] [Related]  

  • 69. In vivo [3H]spiperone binding to the rat hippocampal formation: involvement of dopamine receptors.
    Bischoff S; Bittiger H; Krauss J
    Eur J Pharmacol; 1980 Dec; 68(3):305-15. PubMed ID: 7202494
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Decreased spiroperidol and LSD binding in rat brain after continuous amphetamine.
    Nielsen EB; Nielsen M; Ellison G; Braestrup C
    Eur J Pharmacol; 1980 Aug; 66(2-3):149-54. PubMed ID: 7439269
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Solubilization of 3H-spiperone binding sites from rat brain.
    Gorissen H; Laduron PM
    Life Sci; 1978 Aug; 23(6):575-9. PubMed ID: 692282
    [No Abstract]   [Full Text] [Related]  

  • 72. Competitive inhibition of [3H]spiperone binding to D-2 dopamine receptors in striatal homogenates by organic calcium channel antagonists and polyvalent cations.
    De Vries DJ; Beart PM
    Eur J Pharmacol; 1984 Oct; 106(1):133-9. PubMed ID: 6241565
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Analysis of dopamine interactions with [3H]-spiperone binding sites on rat corpus striatum membranes [proceedings].
    Howlett DR; Nahorski SR
    Br J Pharmacol; 1979 Jul; 66(3):468P-469P. PubMed ID: 526752
    [No Abstract]   [Full Text] [Related]  

  • 74. Demonstration of neuroleptic receptor sites in mouse brain by autoradiography.
    Höllt V; Schubert P
    Brain Res; 1978 Jul; 151(1):149-53. PubMed ID: 679000
    [No Abstract]   [Full Text] [Related]  

  • 75. Chronic sulpiride increased 3H-spiperone binding and calmodulin dependent phosphorylation in rat striatum.
    Lau YS; Runice C; Dowd FJ; Anene C
    Proc West Pharmacol Soc; 1983; 26():139-43. PubMed ID: 6310625
    [No Abstract]   [Full Text] [Related]  

  • 76. Effects of alloxan-induced diabetes on dopaminergic receptors in rat striatum and anterior pituitary.
    Serri O; Renier G; Somma M
    Horm Res; 1985; 21(2):95-101. PubMed ID: 3979949
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Neuroleptic drug-induced dopamine receptor supersensitivity: antagonism by L-prolyl-L-leucyl-glycinamide.
    Chiu S; Paulose CS; Mishra RK
    Science; 1981 Dec; 214(4526):1261-2. PubMed ID: 6117947
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Neuroleptic binding and their effects on the spontaneous and potassium-evoked release of 3H-dopamine from the striatum and of 3H-noradrenaline from the cerebral cortex.
    Arbilla S; Briley MS; Dubocovich ML; Langer SZ
    Life Sci; 1978 Oct; 23(17-18):1775-80. PubMed ID: 31532
    [No Abstract]   [Full Text] [Related]  

  • 79. Enhanced striatal 3H-spiroperidol binding induced by chronic haloperidol treatment inhibited by peptides administered during the withdrawal phase.
    Bhargava HN
    Life Sci; 1984 Feb; 34(9):873-9. PubMed ID: 6142397
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Solubilisation of high-affinity dopamine receptors.
    Gorissen H; Laduron P
    Nature; 1979 May; 279(5708):72-4. PubMed ID: 450076
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.